Evidence map›Paper›PMID 42741491›Full record

ArticleCureus2026

Heart Failure With Preserved Ejection Fraction: A Practical, Stepwise Guide to Evidence-Based Therapy in 2026.

M Nour Chabalout, Mohammad Alazzeh, Dalia Othman, Jaswinder Pal Singh Virk

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M Nour ChabaloutInternal Medicine, Tower Health Medical Group, Phoenixville, USA.
Mohammad AlazzehInternal Medicine, Tower Health Medical Group, Phoenixville, USA.
Dalia OthmanInternal Medicine, Tower Health Medical Group, Phoenixville, USA.
Jaswinder Pal Singh VirkCardiology, Phoenixville Hospital, Phoenixville, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents a large and growing share of the overall heart failure population and remains clinically challenging to manage. HFpEF has historically lacked effective therapies and a clear treatment algorithm accessible to non-specialists. Recent years have brought new pharmacologic options and expanded regulatory approvals, along with combination-therapy modeling suggesting meaningful projected lifetime benefit, yet translation of this evidence into everyday practice remains slow, particularly outside cardiology. Existing reviews synthesizing this evidence are predominantly specialist-oriented, lengthy, and organized by drug class rather than by clinical decision point, leaving a gap for the residents, hospitalists, internists, and primary care physicians who manage most patients with HFpEF. This technical report presents a concise, phenotype-guided, four-step treatment framework, informed by contemporary trial evidence and situated alongside current guideline pathways, together with a brief diagnostic checkpoint, a summary evidence table, and a discussion of common pitfalls, to facilitate rapid clinical application. This framework is an author-derived synthesis rather than a prospectively validated or guideline-endorsed treatment sequence.

Indexed as

glp1 receptor agonistguideline-directed medical therapy (gdmt)heart failure with preserved ejection fraction (hfpef)innovative teaching strategiessodium-glucose cotransporter-2 (sglt2) inhibitors

Identifiers

PMID42741491
PMCPMC13574263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.